Vincristine sulfate

目录号:S1241 别名: Leurocristine

Vincristine sulfate Chemical Structure

Molecular Weight(MW): 923.04

Vincristine sulfate通过与微管蛋白结合而抑制微管聚合,IC50为32 μM。

规格 价格 库存 购买数量  
RMB 582.05 现货
RMB 2229.59 现货
RMB 7118.45 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的2个实验数据:

  • Plk inhibitor cooperates with chemotherapeutic agents. Conditional patched mutant tumor cells were treated with increasing concentrations of the chemotherapeutic agents vincristine alone or in combination with 10 nMol/L BI-2536. Cells were cultured for 48 hours, pulsed with 3H-Td, and harvested for analysis of 3H-Td incorporation at 66 hours.

    Cancer Research, 2013, 73(20): 6310-22 . Vincristine sulfate purchased from Selleck.

    for HXO-RB44 cells, IC50 values for VCR were changed in the different SG600 treatment groups. The results are representative of three independent  experiments and of f our replicates in each experiment.

    Int J Mol Sci 2012 13, 10736-10749 . Vincristine sulfate purchased from Selleck.

产品安全说明书

Microtubule Associated抑制剂选择性比较

生物活性

产品描述 Vincristine sulfate通过与微管蛋白结合而抑制微管聚合,IC50为32 μM。
靶点
Microtubules [1]
(Cell-free assay)
32 μM
体外研究

Vincristine抑制微管蛋白二聚体聚合亚单位,抑制它们的聚合作用,Ki为85 nM。[1]在低浓度时,Vincristine抑制纺锤体,使染色体分离失败,进而导致中期停滞,并抑制有丝分裂。在较高浓度时,Vincristine可能干扰且诱导全部微管解聚。[2] Vincristine 诱导肿瘤细胞凋亡,且抑制SH-SY5Y细胞增殖,IC50为0.1 µM。Vincristine诱导有丝分裂停滞,促进caspase-3和-9及cyclin B的表达,但降低cyclin D的表达。[3] Vincristine通过干扰微管功能而诱导神经毒性形成,这会导致轴突运输堵塞,从而导致轴突变性。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2.2.15 NEDRVXNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NF\aVHIxNTBwNTFOwG0> Mk\KNlQhcA>? Ml:z[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MkHENlU3PjN5Nkm=
HepG2-HBV1.1 NYDBT2JnSXCxcITvd4l{KEG|c3H5 NX7sPZVVOC1yLkWg{txO NHHXS2gzPCCq MVXpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 NFXJTGIzPTZ4M{e2PS=>
HepG2.2.15 NGnyWIVHfW6ldHnvckBCe3OjeR?= M1zSO|AvOSEQvF2= MmOxNlQhcA>? M2S4cpBzd22xdHXzJIhmeGG2aYTpd{BDKH[rcoXzJJBzd3SnaX6g[ZhxemW|c3nvci=> MY[yOVY3Ozd4OR?=
HepG2-HBV1.1 MkToSpVv[3Srb36gRZN{[Xl? MmLtNE4yKM7:TR?= M1vwNVI1KGh? M174WpBzd22xdHXzJIhmeGG2aYTpd{BDKH[rcoXzJJBzd3SnaX6g[ZhxemW|c3nvci=> NHfwfWszPTZ4M{e2PS=>
HepG2-HBV1.1 M2riXWZ2dmO2aX;uJGF{e2G7 NXvIU29wOC5zIN88US=> MlKwOFghcA>? M1LrPJBzd22xdHXzJINmdGxiZYjjdoV1cW:wIH;mJIhmeGG2aYTpd{BDKH[rcoXzJI52[2ynb3PhdJNq\HNiaX7zeIVi\CCxZjDo[ZBifGm2aYOgRkB3cXK3czDEZY5mKHCjcoTpZ4xmew>? MnryNlU3PjN5Nkm=
HepG2-HBV1.1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWWwMlEh|ryP MW[xMVUh\A>? MUXpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjD0bY1mKGSncHXu[IVvfGy7 NILFfYozPTZ4M{e2PS=>
HepG2-HBV1.1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWiwMlEh|ryP MlrJNU02KGR? NV\qe5d[cW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hfGmvZTDk[ZBmdmSnboTsfS=> NFXOW4czPTZ4M{e2PS=>
HepG2-HBV1.1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnlVFNJOC5zIN88US=> NFf3cWsyOi15MjDo NIi4OHZqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KFNvcHjhd4U> NVXSbHN{OjV4NkO3Olk>
HepG2-HBV1.1 M1vrSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYizV4J7OC5zIN88US=> MXOxNk04OiCq M2Wweolv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZZQhWy2yaHHz[S=> M3LXTlI2PjZ|N{[5
Raji MVzGeY5kfGmxbjDBd5NigQ>? M{\vVlAvPcLizszN MnLUO|IhcA>? MX3hZo9tcXOqZYOgZZV1d3CqYXf5xsA> M37EPVI2PDR4M{e3
SK-MEL-28  MlLjSpVv[3Srb36gRZN{[Xl? M37CTFMxKG6P MXu2JIg> MlXybY5lfWOnczDHNwKBm01iY3XscE1kgWOuZTDhdpJme3R? NV2xS4E{OjV|MUOwNVA>
H157 NXWxb4dCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrTRXJKSzVyPUGuNFMhyrFiMD6wOEBucXV{TR?= MWmyOVI2PzlzMR?=
Jurkat M{T6VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYT6NmhyOS1|IH7N M4ixXlQ5yqCq M{WyOWROW09? MlTZ[IVkemWjc3XzJJZq[WKuZTDj[YxtKG63bXLldpMh\G:|ZTDk[ZBmdmSnboTsfS=> NHXETJAzPTF3NkG0Oi=>
CEM MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvvNU0{KG6P MYK0POKhcA>? MlO1SG1UVw>? M4nkN4Rm[3KnYYPld{B3cWGkbHWgZ4VtdCCwdX3i[ZJ{KGSxc3Wg[IVx\W6mZX70cJk> NGTmNm4zPTF3NkG0Oi=>
P12 MmDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHCOI8yNTNibl2= M4LGSVQ5yqCq NGf5THNFVVOR M2rDUoRm[3KnYYPld{B3cWGkbHWgZ4VtdCCwdX3i[ZJ{KGSxc3Wg[IVx\W6mZX70cJk> NEDwcHkzPTF3NkG0Oi=>
KB MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwMEC0PUDDuSByLkCwNFEh|ryP MXiyOVA2QDV{Nh?=
KBv200 (ABCB1) M1u2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\yTWM2OD1yLkO0OlIhyrFiMD6wNFY3KM7:TR?= NEPhRZgzPTB3OEWyOi=>
SUDHL6  NHniVXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEmx[5My6oDLzszN M4XVUlQ5Nzd{IHi= M4\vRYlvcGmkaYTzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> M4Xr[FI1QTZzNkC0
SUDHL6  NELWcXZHfW6ldHnvckBCe3OjeR?= MXex5qCK|ryP MYq3NkBp M3\MVYlv\HWlZYOgd4lodmmoaXPhcpQh[XCxcITveIlkKG2xcoDoc4xw\3liY3jhcodmeyClb4Ty[ZN1\WRid3n0bEBDS0xzMVGgd4lTVkF? NU\wfoUxOjR7NkG2NFQ>
HCT-116 NIjCbZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnke5dkT0l3ME21JI5O MYWyOFkzPzh3Nx?=
SKNBe2C NF;WVWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\QbmxKSzVyPUOyMljDuTRwMDDuUS=> NEn4UY4zPDl{MUmyNC=>
IGNR91 NF71OnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGftN4JKSzVyPUK0MlPDuTFwNzDuUS=> MYOyOFkzOTl{MB?=
SKNAS MmPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTFwNdMxNE4zKG6P NEnETmIzPDl{MUmyNC=>
LAN1 MmfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PQTGlEPTB;Mj6zxtExNjJibl2= NYPEc21xOjR7MkG5NlA>
SHSY5Y Mk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRThwMtMxNE43KG6P MlnrNlQ6OjF7MkC=
A549-WT NF6yOFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4O0XWlEPTB;MUmuOFM4KMLzIECuOVk1KCCwTR?= NUXiO49UOjR6NUi4Nlc>
A549-R MlzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3judWlEPTB;MUKuNVc5KMLzIECuN|M{KCCwTR?= Mn3QNlQ5PTh6Mke=
MCF-7-WT NXy4RWVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfOfFBKSzVyPUG3Mlc2OiEEsTCwMlIyQCBibl2= MVGyOFg2QDh{Nx?=
MCF-7-R NXHwSoxxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rPN2lEPTB;NT61N|khyrFiMD6xOFQhKG6P NV\wco9WOjR6NUi4Nlc>
A549-R M{[wZmN6fG:2b4jpZ4l1gSCDc4PhfS=> NWrV[ZB4UUN3ME2xNk4yPzhiwsGgNE4{OzNibl2= NHLN[|QzPDh3OEiyOy=>
MCF-7-R NF3uTWJEgXSxdH;4bYNqfHliQYPzZZk> M2f3Z2lEPTB;NT61N|khyrFiMD6xOFQhdk1? M3rvWVI1QDV6OEK3
SW620 NIrJc2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoP0TWM2OD15LkiwJOKyKDBwMEigcm0> Mn2xNlQ4OjZ5M{m=
SW620/AD300 M1TWVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHWOplEUUN3ME25NFkvPjBiwsGgPE46OSCwTR?= M3G2[FI1PzJ4N{O5
HEK293/pcDNA3.1 M4LEfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnKNmFMUUN3ME2xMlQ2KMLzIECuNlAhdk1? MnLNNlQ4OjZ5M{m=
HEK293/ABCC1 NUC4[|BTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDa[5lSUUN3ME2xPU4zQSEEsTCyMlA5KG6P MmTxNlQ4OjZ5M{m=
TCC M1LBPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rY[FI1KGh? NFXWTnFKSzVyPUewJI5O NETJVXUzPDdzNkm0OC=>
TCC MoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nD[lQ5KGh? M3zVXGlEPTB;NUCgcm0> MoP4NlQ4OTZ7NES=
HepG2/ADM NFjnZ2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M120[2lEPTB;Mj63PFY{yrFyLkKzO|Eh|ryP NX7j[mt7OjR5MES1OVY>
HepG2 NGLYTm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXuToV7UUN3ME2wMlAyOTYEsUCuNFAyPyEQvF2= NXTYZ2l2OjR5MES1OVY>
MCF-7/ADR MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\tTWM2OD12LkS4NlbDuTBwMkC3NEDPxE1? MVmyOFcxPDV3Nh?=
MCF-7 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjWbJptUUN3ME2wMlAyPToEsUCuNFA3OiEQvF2= NFHPdXQzPDdyNEW1Oi=>
A-172  MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXGwMlHDqM7:TR?= NX;QT45HOjRxN{KgbC=> MXrpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5 NX;QNZNWOjR3M{CyN|U>
U-251MG M1HqRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojjNE4yyqEQvF2= Ml3mNlQwPzJiaB?= MnnUbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=> Mlv5NlQ2OzB{M{W=
DLD-1 MXjGeY5kfGmxbjDBd5NigQ>? MofrNVAxKG6P Ml7nOFghcA>? NYj2flRmeHKxbX;0[ZMhWlWQWEOg[IVu\XSqeXzheIlwdsLi M37BTFI1PDB|NEWz
CCD18Co MXnGeY5kfGmxbjDBd5NigQ>? M3;ZO|ExOCCwTR?= M4fhWlQ5KGh? NIftT3pxem:vb4Tld{BTXU6[MzDk[Y1mfGi7bHH0bY9vyqB? NF7kUIgzPDRyM{S1Ny=>
DLD-1 M{\QXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HvXlAuOTByMDDuUS=> MVG0PEBp NEPsPGRqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NEfxRXYzPDRyM{S1Ny=>
CCD18Co NHTYbm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofrNE0yODByIH7N MUS0PEBp NUPjcnM{cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NXOxV5lkOjR2MEO0OVM>
HepG2 NUfKSGVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfPVllVOjRiaB?= MYHJR|UxRTV{LkZihKnPxE1? MUOyOFM1OTZ6OB?=
HEK293/pcDNA3.1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwMEC0xtExNjByMEOg{txO NETybI8zPDJ6NEe4Ny=>
HEK293/MRP1 MnPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnNOYJ6UUN3ME2wMlA2PcLzMD6wNVIxKM7:TR?= NEWzZZEzPDJ6NEe4Ny=>
Ramos NHz3OlhCeG:ydH;zbZMhSXO|YYm= MXmy5qCK|ryP MVi0PEBp M32xTIlv\HWlZYOgN|QvPiYEsUGuPVImKGGyb4D0c5Nqew>? MofJNlQzPTZ2OUG=
NCI-H1299/pcDNA3 NIPUUJBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGXocYgxNTJyIH7N NHvpTVI6PiCq MkS1bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? M4PXOFI1OTd5MEGy
H1299/ICAM-3 MYTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MkC4NE0zOCCwTR?= MVG5OkBp MlTGbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NFyxNoEzPDF5N{CxNi=>
NCI-H1299/pcDNA3 M1zLVWZ2dmO2aX;uJGF{e2G7 MofZNU82NzFyL{KwxsBvVQ>? MkC0PVYhcA>? NGSyT|BqdmS3Y3XzJINt\WG4YXflJI9nKGOjc4Dhd4V{NTNuIEisJFktKGGwZDDQRXJR NXzvT2xsOjRzN{ewNVI>
H1299/ICAM-3 NF;TPZBHfW6ldHnvckBCe3OjeR?= NVnS[Y1vOS93L{GwM|IxyqCwTR?= NULKRWJ{QTZiaB?= Mn\5bY5lfWOnczDjcIVifmGpZTDv[kBk[XOyYYPld{0{NCB6LDC5MEBidmRiUFHSVC=> M4jkfVI1OTd5MEGy
W1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHu5NZJKSzVyPUCuNFA{OiEQvF2= NEPye3YzPDF2MEG3Oi=>
W1VR NXLkS4RHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwMEW2JO69VQ>? NW\zUIJ[OjRzNECxO|Y>
K562 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDwTWM2OD1yLkCzNkDDuSByLkCwNUAh|ryP NH3XZ3AzPDF|NUmzOy=>
K562/ADR NH7IWYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rifWlEPTB;Mz6yOlEhyrFiMD60NVIh|ryP NEPTfI8zPDF|NUmzOy=>
K562 M13LdmFxd3C2b4Ppd{BCe3OjeR?= NEjYfVMxNjNizszN NEPCeY0zPCCq NUXnb29pcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?= MX[yOFE{PTl|Nx?=
K562/ADR NWfBW|Q{SXCxcITvd4l{KEG|c3H5 MYezJO69VQ>? NHKwcFAzPCCq NED3NFdqdmS3Y3XzJIFxd3C2b4Ppdy=> NY\BNIc{OjRzM{W5N|c>
A549 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTBwMUCgxtEhOC5yMzFOwG0> M{iwOFI{QTdzMEe1
K562 M4TkemNmdGxiVnnhZoltcXS7IFHzd4F6 Mn\oN{44PeLCk{[wxsBvVQ>? Ml;oO|LDqGkEoB?= NVrwbXBocW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NVzweHpPOjN6N{eyNlM>
lucena NH7OZWdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NEDzRWk{Njd34pETOlDDqG6P M4XD[VczyqCqwrC= NFzuR|dvdyCnZn\lZ5Q> MUKyN|g4PzJ{Mx?=
FEPS MkPDR4VtdCCYaXHibYxqfHliQYPzZZk> NWXyeZc4Oy55NfMAl|YxyqCwTR?= M4LnWFczyqCqwrC= M1;tSY5wKGWoZnXjeC=> MkHLNlM5Pzd{MkO=
A2780 NVL1cI1kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWezXXV[UUN3ME2zMlUhdU1? NEDJOY0zOzh{OUKwNy=>
ACHN M163T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLFVI1KSzVyPECuNUBuVQ>? MX:yN|gzQTJyMx?=
U-937 MmD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33S[2lEPTB:M{Sgcm0> M3;3b|I{QDJ7MkCz
Jurkat NI\Kd2xCeG:ydH;zbZMhSXO|YYm= MX[1xsDPxGdxbX|CpC=> NILpdVkzPCCq M3TJSYlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl? NUn1N2NoOjN6MUC0NFk>
Jurkat M1rFdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWO1xsDPxGdxbX|CpC=> NITQNlIzPCCq Ml3ZZZJz\XO2IFr1dotifCClZXzsd{BqdiCJMj;NJJBp[XOn NUC5[3J3OjN6MUC0NFk>
Hep-2 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmH1TWM2OD1yLkC0xtExNjBzIN88US=> M4KzbVI{PzhyNEK0
Hep-2/v NGiwVZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1yyZmlEPTB;MT64xtExNjJyIN88US=> M17HO|I{PzhyNEK0
SGC-7901 Ml;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIOxO2kxNTFyIN88[{9udA>? NU\RZZJtOjRxNEivO|IhcA>? NHnNVmZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> MWKyN|c1OzV5Mh?=
SGC-7901/VCR M{P1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULN[XJtOC1zMDFOwIcwdWx? MnzRNlQwPDhxN{KgbC=> MUHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= NEXVUlEzOzd2M{W3Ni=>
SGC-7901 M4fnPGFxd3C2b4Ppd{BCe3OjeR?= NYCzOHlXcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?= NEL4ZVIzOzd2M{W3Ni=>
SGC-7901/VCR Mm\YRZBweHSxc3nzJGF{e2G7 NHjLXIJqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 M17kXlI{PzR|NUey
KB-3-1 M4K3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\EWGlEPTB;MT62OkDDuSByLkG2NkDPxE1? MYmyN|Y4OzR2NR?=
KB-C2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXMT5JKSzVyPUKwNk42PiEEsTC0Nk41QDFizszN NHyw[IozOzZ5M{S0OS=>
KB-3-1 NX;2b|B5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PyNmlEPTB;MT6yOkDDuSByLkCyO{DPxE1? M3vpXVI{Pjd|NES1
KB-V1 MkS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzyc3llUUN3ME2yNFgvQDViwsGgNlAvPCEQvF2= NUn1UYgzOjN4N{O0OFU>
HEK293/pcDNA3.1 M1n3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEW2cYZKSzVyPUK0MlEhyrFiMD6yNFQh|ryP MUKyN|Y4OzR2NR?=
HEK293/ABCB1 NEPyZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHkTWtHUUN3ME2zOVEzNjhiwsGgN|c5NjN7MTFOwG0> M2rXSVI{Pjd|NES1
A549/EGFP  MlfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nMd|AvODFvMUCwNEDPxE1? M2fvNmlEPTB;OE[uO{DDuSB{OT6xJO69VQ>? MlntNlM3OzR{OEK=
A549/Slug NGDnbnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUT0WWVUOC5yMT2xNFAxKM7:TR?= NVvmS3ZLUUN3ME25MlchyrFiMz6xJO69VQ>? MXiyN|Y{PDJ6Mh?=
JFCR39  NHW1dlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHz6T4YyKML3TR?= MnrSNlQhcA>? NYfmcpp3TE2VTx?= MXztZZJs\WSueTDpcoNz\WG|ZYOgeIhmKG63bXLldkBw\iCJMj;NJJBp[XOnIHPlcIx{ NUW4OJZqOjN3OUiyO|Y>
A549 NVfYRmIxTnWwY4Tpc44hSXO|YYm= NEDQOGUyODBibl2= MmrPNVYhcA>? NFvhXHFFVVOR NX3NOZk5dGWjZIOgeI8h[SCub4PzJI9nKG2rY4LveJVjfWyncx?= MUCyN|U6QDJ5Nh?=
SGC7901 Mor6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zmNGlEPTB;MT6yOwKBkcLz4pEJNE4yOSEQvHevcYw> NUfjOYoyOjN3NkS0PFI>
SGC7901/LV-NC NEDINmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\FTWM2OD1zLke35qCKyrIkgJmwMlE3KM7:Zz;tcC=> MUiyN|U3PDR6Mh?=
SGC7901/LV-SGO1 NE\BTlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLjTWM2OD12LkO25qCKyrIkgJmwMlM4KM7:Zz;tcC=> MlyyNlM2PjR2OEK=
SGC7901/VCR M2T1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkL0TWM2Oz1{MD61N-KBkcLz4pEJNU46PiEQvHevcYw> NIHJVpMzOzV4NES4Ni=>
SGC7901/VCR-NC MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfhSI9KSzVyPUG5Mlg36oDLwsJihKkzNjBzIN88[{9udA>? MYCyN|U3PDR6Mh?=
SGC7901/VCR-si-SGO1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfmTWM2OD14LkG45qCKyrIkgJmxMlA{KM7:Zz;tcC=> MkXNNlM2PjR2OEK=
SGC7901/ADR NIH6VWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnq1TWM2OD15Lki15qCKyrIkgJmwMlY1KM7:Zz;tcC=> Ml30NlM2PjR2OEK=
SGC7901/ADR-NC MljsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvRWYtKSzVyPUiuPVPjiIoEsfMAjVAvPjhizsznM41t MWmyN|U3PDR6Mh?=
SGC7901/ADR-si-SGO1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonSTWM2OD1|LkS25qCKyrIkgJmwMlI6KM7:Zz;tcC=> MYSyN|U3PDR6Mh?=
SH-SY5Y  MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUC3[2tROC5yMEGtNVAh|ryP M2[zb|I1KGh? MVTJR|UxRTBwMUGzxtExNjBzMjFOwG0> MV:yN|EzQTB4NR?=
SH-SY5Y  NGnLc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLNNE4xODFvMUCg{txO NIDZPFM1QCCq Ml3tTWM2OD1yLkC3POKyOC5yMEmg{txO M3ywVlI{OTJ7ME[1
SH-SY5Y  M{f3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHTNE4xODFvMUCg{txO NWLYd3pmPzJiaB?= Mo\0TWM2OD1yLkC1NeKyOC5yMEig{txO MX:yN|EzQTB4NR?=
SH-SY5Y MnXpRZBweHSxc3nzJGF{e2G7 NY\2bWRkOC5zIN88US=> NGj2O4oxNTJ2IHi= NV;3eoNGcW6mdXPld{BieG:ydH;zbZMhd2ZiU1itV3k2YSClZXzsd{Bnd2yub4fpcoch[2WubDDjfYNt\SCjcoLld5Qh[XRidHjlJGczN01icHjhd4U> MX[yN|EzQTB4NR?=
SH-SY5Y NIrB[2tCeG:ydH;zbZMhSXO|YYm= M3zpcVAvOSEQvF2= M4H5TlAuOjRiaB?= MWPpcoR2[2W|IH3peI91cWNiYYLy[ZN1yqB? NIDoNIIzOzF{OUC2OS=>

... Click to View More Cell Line Experimental Data

体内研究 Vincristine 按3 mg/kg剂量单独腹腔注射给药携带双侧皮下移植瘤RH12或RH18的小鼠,平均生长延迟120天和52天以上,且再植指数分别为0.06%和5%。[5] Vincristine 处理小鼠,通过宿主细胞介导的血管效应及直接的微管蛋白介导的的细胞毒性作用而对皮下结肠38肿瘤起作用。Vincristine (5 mg/kg) 降低肿瘤血流量,降低近75%。[6]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[1]
+ 展开
  • Cell lines: B16 黑色素瘤细胞
  • Concentrations: 10 nM
  • Incubation Time: 3 天
  • Method: 细胞按5 × 104 cells/mL的浓度接种在含2 mL培养基的35-mm 实验板上,在37°C下 含5% CO2 和95% 空气 的环境下生长24小时。然后使用有或无10 nM药物的新鲜培养基更换原来的培养基,继续增殖3天。使用胰蛋白酶和EDTA将细胞分离后,每天使用库氏计数器完成细胞计数
    (Only for Reference)
动物实验:[5]
+ 展开
  • Animal Models: 携带人类横纹肌肉瘤移植瘤Rh12的鼠
  • Formulation: 水溶液
  • Dosages: 3 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (108.33 mM)
Water 60 mg/mL (65.0 mM)
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
Saline
30 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 923.04
化学式

C46H58N4O14S

CAS号 2068-78-2
稳定性 powder
in solvent
别名 Leurocristine

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03571321 Not yet recruiting Acute Lymphoblastic Leukemia|ALL Childhood|ALL University of Chicago|Incyte Corporation September 5 2019 Phase 1
NCT03349281 Recruiting Refractory Acute Lymphoblastic Leukemia|Relapsed Acute Lymphoblastic Leukemia Julio Barredo|Takeda|University of Miami March 2019 Phase 1
NCT03710772 Not yet recruiting CD20 Positive|Mantle Cell Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI) January 31 2019 Phase 2
NCT03613428 Not yet recruiting Acute T Cell Leukemia Sichuan University December 1 2018 Phase 1|Phase 2
NCT03742258 Not yet recruiting Diffuse Large B-Cell Lymphoma|Diffuse Large B-Cell Lymphoma Activated B-Cell Type|Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type|Diffuse Large B-Cell Lymphoma Not Otherwise Specified|High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements|High Grade B-Cell Lymphoma Not Otherwise Specified|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Northwestern University|National Cancer Institute (NCI) December 29 2018 Phase 1
NCT03704714 Not yet recruiting Aggressive Non-Hodgkin Lymphoma|B-Cell Non-Hodgkin Lymphoma|CD20 Positive|Diffuse Large B-Cell Lymphoma Unclassifiable|Intravascular Large B-Cell Lymphoma|Primary Mediastinal (Thymic) Large B-Cell Lymphoma|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma Northwestern University|Bristol-Myers Squibb (BMS)|National Cancer Institute (NCI) November 8 2018 Phase 1|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?

  • 回答:

    According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

Microtubule Associated Signaling Pathway Map

相关Microtubule Associated产品

Tags: 购买Vincristine sulfate | Vincristine sulfate供应商 | 采购Vincristine sulfate | Vincristine sulfate价格 | Vincristine sulfate生产 | 订购Vincristine sulfate | Vincristine sulfate代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID